Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6349 USD | +26.90% | -8.00% | +11.39% |
May. 30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
May. 23 | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
Evolution of the average Target Price on Viracta Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Viracta Therapeutics, Inc.
Oppenheimer | |
RBC Capital Markets | |
HC Wainwright | |
SVB Leerink | |
Evercore ISI |
EPS Revisions
- Stock Market
- Equities
- VIRX Stock
- Consensus Viracta Therapeutics, Inc.